Dupuytren's Disease Market Report 2026

The dupuytren's disease market size has grown strongly in recent years. It will grow from $4.51 billion in 2025 to $4.76 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to aging population growth, orthopedic disorder prevalence, surgical treatment availability, clinical diagnosis standardization, hand therapy adoption.

The dupuytren's disease market size is expected to see strong growth in the next few years. It will grow to $5.94 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to biologic therapy development, minimally invasive innovation, outpatient care expansion, patient quality of life focus, rehabilitation service growth. Major trends in the forecast period include growing adoption of minimally invasive treatment options, increasing use of enzyme injection therapies, rising preference for outpatient surgical procedures, expansion of early diagnosis and physical examination, growing focus on post-treatment rehabilitation.

The increasing adoption of minimally invasive treatments is expected to drive the growth of the Dupuytren’s disease market in the coming years. Minimally invasive treatments are medical procedures performed with small incisions or minimal tissue disruption, resulting in less pain, faster recovery, and reduced scarring. Their adoption is growing as patients and clinicians prefer procedures with shorter healing times, lower discomfort, and fewer complications compared to traditional open surgeries. The Dupuytren’s disease market supports this trend by offering minimally invasive options that enhance hand function, reduce finger contractures, and improve recovery outcomes for affected individuals. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based non-profit organization, minimally invasive procedures increased by 7% in 2023, outpacing the growth rate of surgical procedures by 2%. Hand surgeries such as carpal tunnel, arthritis, and trigger finger totaled 207,887 procedures, a 2% rise from 2022. Therefore, the rise of minimally invasive treatments is driving the growth of the Dupuytren’s disease market.

Major companies in the Dupuytren’s disease market are focusing on clinical trials to develop innovative, first-line, disease-modifying treatments aimed at slowing or reversing fibrotic progression. Clinical trials are structured research studies designed to evaluate the safety, efficacy, and potential side effects of new drugs, therapies, or medical procedures in human participants before regulatory approval and widespread use. For instance, in April 2023, Ventoux Biosciences, a US-based biopharmaceutical company specializing in non-surgical Dupuytren’s therapies, announced positive preclinical results for its lead fibrosis treatment, VEN-201. This repurposed drug demonstrated efficacy in reducing skin fibrosis in mouse models of Dupuytren’s contracture, prompting the company to initiate fundraising efforts to advance VEN-201 into clinical development as a potential disease-modifying therapy.

In November 2024, John Elway, a US-based retail company, partnered with Endo Inc. for an undisclosed amount. Through this collaboration, John Elway aims to raise awareness of Dupuytren's contracture and promote early diagnosis and treatment by advocating XIAFLEX (collagenase clostridium histolyticum) as a non-surgical therapeutic option. Endo Inc. is a US-based pharmaceutical company that manufactures medications for Dupuytren's contracture.

Major companies operating in the dupuytren's disease market are Pfizer Inc., Aetna Inc., Mayo clinic, Penn Medicine, Mercy Health, Endo Inc., Resilience Orthopedics, Raleigh Orthopaedic, Hoag Orthopedic Institute, OSS Health, Connext Inc., University of Utah Health, Ventoux Biosciences Inc., Auxilium Pharmaceuticals, 180 Life Sciences Corp., Brigid Freyne MD, Nantong Jinghua Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Actiza Pharmaceutical Private Limited, Spear Pharmaceuticals.

North America was the largest region in the dupuytren's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dupuytren's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dupuytren's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dupuytren's disease market by increasing costs of imported surgical instruments, enzyme injections, and diagnostic equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported medical devices. These tariffs raise treatment costs by increasing procedural and biologic therapy expenses, impacting patient access to minimally invasive interventions. However, they encourage domestic production of orthopedic tools and injectables, fostering regional manufacturing and improving long-term supply stability.

The dupuytren's disease market research report is one of a series of new reports that provides dupuytren's disease market statistics, including dupuytren's disease industry global market size, regional shares, competitors with a dupuytren's disease market share, detailed dupuytren's disease market segments, market trends and opportunities, and any further data you may need to thrive in the dupuytren's disease industry. This dupuytren's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dupuytren's disease, also known as Dupuytren's contracture, is a condition that affects the connective tissue (fascia) in the palm and fingers, leading to thickening and tightening. Over time, this causes the fingers to bend toward the palm, making it difficult to straighten them or perform everyday tasks.

The main types of Dupuytren's disease are Type I, Type II, and Type III. Type I is the most severe form, often occurring in individuals under 50 years of age. Treatment options include surgery, radiation therapy, needle aponeurotomy, steroid injections, enzyme injections, occupational therapy, and others. These treatments are administered via various routes, including oral and parenteral methods. Diagnosis is carried out through methods such as physical examination, X-ray, and others. End users include hospitals, clinics, academic and research institutes, and other healthcare facilities.

The dupuytren's disease market consists of revenues earned by entities by providing services such as diagnosis, physical therapy, minimally invasive treatments, surgical procedures, post-treatment rehabilitation, and related pharmaceutical and medical device solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The dupuytren's disease market also includes sales of products such as collagenase injections, anti-inflammatory medications, splints, orthopedic braces, surgical instruments, and laser or ultrasound therapy devices used for treatment and management of the condition. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.